Saturday, 31 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleMIT Technology Review

Three things in AI to watch, according to a Nobel-winning economist

View original at technologyreview.com
MIT Technology Review - Ai Research Title: Three things in AI to watch, according to a Nobel-winning economist Date: 2026-05-11 17:35 Source: https://www.technologyreview.com/2026/05/11/1137090/three-things-in-ai-to-watch-according-to-a-nobel-winning-economist/ <p><em>This story originally appeared in The Algorithm, ou…
Opening lines of the source · MIT Technology Review · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Some of the most influential research about AI's impact on work may increasingly come from the companies with the most to gain from favorable conclusions, which is a concerning dynamic

    60% confidence
  • There is a huge amount of uncertainty in the AI economy; conflicting signals will persist — anecdotes about worsening job markets for college graduates alongside no measurable effect on productivity

    60% confidence
  • AI agents are better thought of as tools to augment particular pieces of someone's work than something malleable enough to handle a person's whole job

    60% confidence
  • Corporate AI use should be taxed and workers displaced by AI-driven layoffs should receive compensation as part of a jobs guarantee

    60% confidence
  • Using AI agents as a one-to-many replacement for human workers is a losing proposition

    60% confidence
  • AI companies have strong incentives to shape the economic narrative around their technology, raising the risk that in-house economists are hired to further viewpoints or hype rather than conduct genuine research

    60% confidence
  • AI would give only a small boost to US productivity and would not obviate the need for human work; it is okay at automating certain tasks, but some jobs will be perfectly fine

    60% confidence
  • One of the key signals to watch for AI's economic impact is the creation of apps that make AI easier for average workers to use productively

    60% confidence
  • It makes sense for AI companies to hire economists because public skepticism about AI — largely driven by job concerns — is growing

    60% confidence
  • Some previously skeptical economists have become more open to the idea that AI could cause seismic disruption to the labor market

    60% confidence
  • Studies repeatedly find that AI is not affecting employment rates or layoffs

    60% confidence
  • Whether AI agents will supercharge AI's impact on jobs depends on whether they can eventually handle the orchestration between tasks that humans do naturally; many jobs will be spared if agents cannot fluidly switch between tasks

    60% confidence
  • AI has not yet seen the development of apps with the same usability as transformative software like PowerPoint or Microsoft Word, which is why AI has not yet shown a seismic impact on the job market or economy

    60% confidence
  • An x-ray technician juggles 30 different tasks — from taking patient histories to organizing mammogram archives — and an AI would need many individual tools or protocols to replicate the natural switching a human does

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com